Center for Pediatric Infectious Diseases, Cleveland Clinic Children's, Cleveland, Ohio, USA.
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Pediatr Transplant. 2024 Nov;28(7):e14870. doi: 10.1111/petr.14870.
Vaccinating pediatric solid organ transplant candidates against measles and varicella is crucial due to the risk of severe disease in immunosuppressed recipients and general avoidance of live virus vaccines post-transplantation. The world saw a resurgence of measles starting 2012 prompting the American Society of Transplantation in 2015 to release guidelines on recognition, prevention, and post-exposure prophylaxis of this disease in solid transplant recipients. This study aims to assess the extent of incomplete immunity to these viruses in candidates and the approach to immunity optimization during a period of heightened awareness.
A cross-sectional study from 2012 to 2016 at Cleveland Clinic Children's included pediatric solid organ transplant candidates. Data on vaccination history, serology, and demographics were collected. Incomplete immunity was defined by incomplete vaccination or seronegativity.
Among 91 candidates, 54.9% had complete varicella vaccination. Serological varicella immunity among patients tested varied by age: < 7 years, 50.0% positive in patients with complete schedules, none in the incomplete; ≥ 7 years, 50.0% positive in patients with complete schedules, 65.5% in the incomplete. For measles, 69.2% had complete vaccination, with immunity varying by age among those tested: < 7 years, 84.6% positive in patients with complete schedules, 42.9% in the incomplete; ≥ 7 years, 81.0% with complete, 62.5% with incomplete. Only 31.1% of those who qualified for a varicella additional dose and 28% who qualified for an additional measles dose received it, respectively.
Incomplete immunity to varicella and measles was prevalent in pediatric solid organ transplant candidates at our center during the study period. Despite an increase in global measles activity, our efforts to optimize immunity through additional vaccine doses were only partially successful. Future research should focus on addressing strategies and understanding barriers to ensure timely vaccination for this vulnerable population prior to transplant, especially during periods of increased viral activity.
由于免疫抑制受者患严重疾病的风险以及移植后普遍避免使用活病毒疫苗,为小儿实体器官移植候选者接种麻疹和水痘疫苗至关重要。自 2012 年以来,世界范围内麻疹疫情再次爆发,促使美国移植学会于 2015 年发布了关于实体移植受者中这种疾病的识别、预防和暴露后预防的指南。本研究旨在评估候选者对这些病毒的不完全免疫程度以及在提高认识期间优化免疫的方法。
2012 年至 2016 年在克利夫兰诊所儿童中心进行了一项横断面研究,纳入小儿实体器官移植候选者。收集了疫苗接种史、血清学和人口统计学数据。不完全免疫定义为不完全接种疫苗或血清学阴性。
在 91 名候选者中,54.9%的人完全接种了水痘疫苗。接受检测的患者的血清水痘免疫力因年龄而异:<7 岁,完全接种疫苗的患者中 50.0%为阳性,不完全接种的患者中无阳性;≥7 岁,完全接种疫苗的患者中 50.0%为阳性,不完全接种的患者中 65.5%为阳性。对于麻疹,69.2%的人完全接种了疫苗,接受检测的患者中免疫因年龄而异:<7 岁,完全接种疫苗的患者中 84.6%为阳性,不完全接种的患者中 42.9%为阳性;≥7 岁,完全接种疫苗的患者中 81.0%为阳性,不完全接种的患者中 62.5%为阳性。只有 31.1%符合接种水痘额外剂量的条件,28%符合接种麻疹额外剂量的条件,分别有 31.1%和 28%的人接受了相应的疫苗接种。
在研究期间,我们中心的小儿实体器官移植候选者对水痘和麻疹的免疫不完全。尽管全球麻疹活动增加,但我们通过额外疫苗剂量优化免疫的努力仅部分成功。未来的研究应重点关注策略和了解障碍,以确保在移植前为这一脆弱人群及时接种疫苗,尤其是在病毒活动增加期间。